Emmes, a global, full-service CRO supporting advancement of public health and biopharmaceutical innovation and portfolio company of Behrman Capital, has acquired Casimir.
Casimir is a U.S.-based CRO with experience across more than 20 diseases. The firm works with regulators, sponsors, and patients to develop outcome measures that can capture the nuances of disease progression and treatment benefits.
The deal represents Emmes’ fourth acquisition since Behrman’s 2019 investment in the firm. Casimir will accelerate Emmes’ strategic focus on rare disease research and will position the firm as a leading CRO for rare and orphan disease R&D.
“The acquisition of Casimir represents another important step towards accelerating Emmes’ core focus on rare diseases,” commented Grant Behrman, managing partner of Behrman Capital. “This transaction marks an additional expansion of the Company’s platform under our ownership period with the enhancement of Casimir’s leading expertise and capabilities. Emmes is in an incredibly strong position to deliver value to all its stakeholders, and we continue to be proud in having helped to drive the Company’s upward growth trajectory.”